NEW YORK – Syapse said on Tuesday that it has partnered with Illumina to assess uptake and actionability of comprehensive genomic profiling in the community oncology health system setting.
The firms will evaluate single-gene, small panel, and comprehensive genomic profiling tests in advanced cancer patients. A focus of the study, which will use data from the Syapse Learning Health Network, the firm's data aggregation platform, will be trends in testing approaches over time and actionability of results.
Syapse will conduct the analysis with input from Illumina. Financial and other terms of the deal were not disclosed.
"Our organizations hope that the results of this work will help to inform clinical decision-making in the community health system setting so that more patients with cancer who may benefit from a targeted therapy are presented with the option of pursuing that treatment in a timely way," Syapse said in an email.
Based in San Francisco, Syapse makes software to support precision oncology care and drug discovery. It has signed multiple partnerships around oncology data, including with Pfizer, Amgen, Seoul National University Hospital, and the US Food and Drug Administration Oncology Center of Excellence.
Upon completion of the analysis, the firms hope to present their results at a conference and publish them in a peer-reviewed journal, Syapse said.